Genelux Reports Publication Of Positive Topline Data From Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) In Platinum-Resistant or Refractory Ovarian Cancer
Portfolio Pulse from Benzinga Newsdesk
Genelux has reported positive topline data from its Phase 2 VIRO-15 trial evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in platinum-resistant or refractory ovarian cancer. The trial met its primary endpoint of objective response rate with deep and durable responses.
May 25, 2023 | 8:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genelux's positive topline data from the Phase 2 VIRO-15 trial of Olvi-Vec in platinum-resistant ovarian cancer may boost investor confidence.
The positive topline data from the Phase 2 VIRO-15 trial indicates that Olvi-Vec has met its primary endpoint in treating platinum-resistant ovarian cancer. This is likely to boost investor confidence in Genelux's product pipeline and may lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100